Ultomiris

Active Ingredient(s): Ravulizumab-cwvz
FDA Approved: * December 21, 2018
Pharm Company: * ALEXION PHARM

Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5).[3][2] Paroxysmal nocturnal hemoglobinuria is characterized by red blood cell destruction, anemia (red blood cells unable to carry enough oxygen to tis... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Ultomiris 300 mg/30ml Intravenous Solution, Concentrate

NDC: 25682-022

Labeler:

Alexion Pharmaceuticals Inc.

Ultomiris 300 mg/3ml Intravenous Solution, Concentrate

NDC: 25682-025

Labeler:

Alexion Pharmaceuticals Inc.

Ultomiris 1100 mg/11ml Intravenous Solution, Concentrate

NDC: 25682-028

Labeler:

Alexion Pharmaceuticals Inc.